Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Media Releases

ESMO Congress 2024 Press Release

Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group of Women with Early-Stage Disease

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers

ESMO Congress 2024 Press Release

From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing, the ESMO Congress 2024 Takes a Holistic View of Oncology

The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand

Media Alert

ESMO 2024 Press Conference

The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.

ESMO Congress 2024 Press Release

Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe

According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers

ESMO Gynaecological Cancers Congress 2024 Press Release

Cross-Border Network of European Specialists Provides New Treatment Options For Women with Complex Rare Gynaecological Cancers

Cross-border tumour boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynaecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress 2024

Event Announcement

ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June

The European Society for Medical Oncology is pleased to announce the ESMO Gastrointestinal Cancers Congress 2024, the scientific congress entirely dedicated to the presentation of advances and discussions around the prevention, diagnosis and management of malignancies of the gastrointestinal tract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.